Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
AGNPF Stock — Algernon Pharmaceuticals Inc
Algernon Pharmaceuticals Inc (AGNPF)
Updated October 9, 2026.
AGNPF is a Stock. Total return is -99.8% over the past 10.6 years, 456.4 points behind SPY at 356.6%.
Grey Matters Health Inc. (formerly Algernon Pharmaceuticals Inc.) is a clinical-stage pharmaceutical development company based in Vancouver that focuses on developing therapeutic drugs for non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke treatment, with a pipeline that includes repirinast for chronic kidney disease and N,N-Dimethyltryptamine for strokes and traumatic brain injuries. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage drug development with a higher risk and longer timeline to potential profitability typical of pre-commercial biotech companies.
AGNPF dividend yield and income
Price as of 2026-10-09.
The payment date is 10/17/2018.
AGNPF performance versus SPY
Price and return data through 2026-10-09.
Total return is -99.8% over the past 10.6 years, 456.4 points behind SPY at 356.6%. Over the past year its total return — price change plus distributions reinvested — is -49.1%. Its deepest 1-year drawdown was 64.1%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -18.8% | — |
| 3M | -6.5% | — |
| 6M | -25.2% | — |
| YTD | -40.0% | — |
| 1Y | -49.1% | — |
| 2Y CAGR | — | -32.30% |
| 3Y CAGR | — | -32.50% |
| 5Y CAGR | — | -53.30% |
| 10Y CAGR | — | -38.30% |
| Since inception (10.6 years) | -99.8% | -44.20% |
AGNPF key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 03/11/2016
- Distribution frequency
- None
- Last close
- $0.30 (stale; as of 2026-10-09)
- Market cap
- $2,890,721
- Average volume
- 5000.0
- Payment date
- 10/17/2018
- Beta
- 1.092
- Payout ratio
- 0.0%
- EPS
- $-0.36
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
AGNPF risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 64.1%.
Who may consider AGNPF — and who may not
It is a weaker fit for investors who need monthly cash flow (AGNPF does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on AGNPF
Frequently asked questions
Does AGNPF pay monthly?
No. AGNPF does not currently distribute.
When does AGNPF pay a dividend?
AGNPF does not currently distribute. The payment date is 10/17/2018.
How has AGNPF performed?
Total return is -99.8% over the past 10.6 years, 456.4 points behind SPY at 356.6%. Over the past year its total return — price change plus distributions reinvested — is -49.1%. Its deepest 1-year drawdown was 64.1%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.